US Capitol Capsule: Will Myriad BRCA case relieve biopharma's patent anxiety?
04:20 EDT 16 Jul 2012 | SCRIP
Dumbfounded by the US Supreme Court's 20 March decision invalidating diagnostic methods patents held by Prometheus Laboratories, the biopharma industry is bracing for the next court battle about what is or isn't patentable subject matter.....
Original Article: US Capitol Capsule: Will Myriad BRCA case relieve biopharma's patent anxiety?
More From BioPortfolio on "US Capitol Capsule: Will Myriad BRCA case relieve biopharma's patent anxiety?"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
